Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials
To test the hypothesis that albumin administration is not associated with excess mortality. Computer searches of the MEDLINE and EMBASE databases, the Cochrane Library, and Internet documents; hand searching of medical journals; inquiries to investigators and medical directors; and review of referen...
Uloženo v:
| Vydáno v: | Annals of internal medicine Ročník 135; číslo 3; s. 149 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
07.08.2001
|
| Témata: | |
| ISSN: | 0003-4819 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To test the hypothesis that albumin administration is not associated with excess mortality.
Computer searches of the MEDLINE and EMBASE databases, the Cochrane Library, and Internet documents; hand searching of medical journals; inquiries to investigators and medical directors; and review of reference lists.
Randomized, controlled trials comparing albumin therapy with crystalloid therapy, no albumin, or lower doses of albumin.
Two investigators independently extracted data. The primary end point was relative risk for death. Criteria used to assess methodologic quality were blinding, method of allocation concealment, presence of mortality as a study end point, and crossover. Small-trial bias was also investigated.
Fifty-five trials involving surgery or trauma, burns, hypoalbuminemia, high-risk neonates, ascites, and other indications were included. Albumin administration did not significantly affect mortality in any category of indications. For all trials, the relative risk for death was 1.11 (95% CI, 0.95 to 1.28). Relative risk was lower among trials with blinding (0.73 [CI, 0.48 to 1.12]; n = 7), mortality as an end point (1.00 [CI, 0.84 to 1.18]; n = 17), no crossover (1.04 [CI, 0.89 to 1.22]; n = 35), and 100 or more patients (0.94 [CI, 0.77 to 1.14]; n = 10). In trials with two or more such attributes, relative risk was further reduced.
Overall, no effect of albumin on mortality was detected; any such effect may therefore be small. This finding supports the safety of albumin. The influence of methodologic quality on relative risk for death suggests the need for further well-designed clinical trials. |
|---|---|
| AbstractList | To test the hypothesis that albumin administration is not associated with excess mortality.
Computer searches of the MEDLINE and EMBASE databases, the Cochrane Library, and Internet documents; hand searching of medical journals; inquiries to investigators and medical directors; and review of reference lists.
Randomized, controlled trials comparing albumin therapy with crystalloid therapy, no albumin, or lower doses of albumin.
Two investigators independently extracted data. The primary end point was relative risk for death. Criteria used to assess methodologic quality were blinding, method of allocation concealment, presence of mortality as a study end point, and crossover. Small-trial bias was also investigated.
Fifty-five trials involving surgery or trauma, burns, hypoalbuminemia, high-risk neonates, ascites, and other indications were included. Albumin administration did not significantly affect mortality in any category of indications. For all trials, the relative risk for death was 1.11 (95% CI, 0.95 to 1.28). Relative risk was lower among trials with blinding (0.73 [CI, 0.48 to 1.12]; n = 7), mortality as an end point (1.00 [CI, 0.84 to 1.18]; n = 17), no crossover (1.04 [CI, 0.89 to 1.22]; n = 35), and 100 or more patients (0.94 [CI, 0.77 to 1.14]; n = 10). In trials with two or more such attributes, relative risk was further reduced.
Overall, no effect of albumin on mortality was detected; any such effect may therefore be small. This finding supports the safety of albumin. The influence of methodologic quality on relative risk for death suggests the need for further well-designed clinical trials. To test the hypothesis that albumin administration is not associated with excess mortality.PURPOSETo test the hypothesis that albumin administration is not associated with excess mortality.Computer searches of the MEDLINE and EMBASE databases, the Cochrane Library, and Internet documents; hand searching of medical journals; inquiries to investigators and medical directors; and review of reference lists.DATA SOURCESComputer searches of the MEDLINE and EMBASE databases, the Cochrane Library, and Internet documents; hand searching of medical journals; inquiries to investigators and medical directors; and review of reference lists.Randomized, controlled trials comparing albumin therapy with crystalloid therapy, no albumin, or lower doses of albumin.STUDY SELECTIONRandomized, controlled trials comparing albumin therapy with crystalloid therapy, no albumin, or lower doses of albumin.Two investigators independently extracted data. The primary end point was relative risk for death. Criteria used to assess methodologic quality were blinding, method of allocation concealment, presence of mortality as a study end point, and crossover. Small-trial bias was also investigated.DATA EXTRACTIONTwo investigators independently extracted data. The primary end point was relative risk for death. Criteria used to assess methodologic quality were blinding, method of allocation concealment, presence of mortality as a study end point, and crossover. Small-trial bias was also investigated.Fifty-five trials involving surgery or trauma, burns, hypoalbuminemia, high-risk neonates, ascites, and other indications were included. Albumin administration did not significantly affect mortality in any category of indications. For all trials, the relative risk for death was 1.11 (95% CI, 0.95 to 1.28). Relative risk was lower among trials with blinding (0.73 [CI, 0.48 to 1.12]; n = 7), mortality as an end point (1.00 [CI, 0.84 to 1.18]; n = 17), no crossover (1.04 [CI, 0.89 to 1.22]; n = 35), and 100 or more patients (0.94 [CI, 0.77 to 1.14]; n = 10). In trials with two or more such attributes, relative risk was further reduced.DATA SYNTHESISFifty-five trials involving surgery or trauma, burns, hypoalbuminemia, high-risk neonates, ascites, and other indications were included. Albumin administration did not significantly affect mortality in any category of indications. For all trials, the relative risk for death was 1.11 (95% CI, 0.95 to 1.28). Relative risk was lower among trials with blinding (0.73 [CI, 0.48 to 1.12]; n = 7), mortality as an end point (1.00 [CI, 0.84 to 1.18]; n = 17), no crossover (1.04 [CI, 0.89 to 1.22]; n = 35), and 100 or more patients (0.94 [CI, 0.77 to 1.14]; n = 10). In trials with two or more such attributes, relative risk was further reduced.Overall, no effect of albumin on mortality was detected; any such effect may therefore be small. This finding supports the safety of albumin. The influence of methodologic quality on relative risk for death suggests the need for further well-designed clinical trials.CONCLUSIONSOverall, no effect of albumin on mortality was detected; any such effect may therefore be small. This finding supports the safety of albumin. The influence of methodologic quality on relative risk for death suggests the need for further well-designed clinical trials. |
| Author | Wilkes, M M Navickis, R J |
| Author_xml | – sequence: 1 givenname: M M surname: Wilkes fullname: Wilkes, M M email: mwilkes@hygeiaassociates.com organization: Hygeia Associates, 17988 Brewer Road, Grass Valley, CA 95949, USA. mwilkes@hygeiaassociates.com – sequence: 2 givenname: R J surname: Navickis fullname: Navickis, R J |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11487482$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kMlOwzAURb0oogP8AvIKNrh4iGNnWVVMUiVYwDp6SRxh5NjFdiqVryeIYfOOru7RXbwlmvngDUJXjK6V4OUNpVSQQrOKMCGJIJxSRjVVlEwNVTO0-DfmaJnS-3fUXJ-iOWOFVoXmC2SeIVvjM05jPNgDOAx9NhG_jQN4DK4ZBzuxm65NOU5y8Gu8wYPJQMCDOyabcOhxBN-FwX6a7hq3wecYnDMdztGCS2fopJ9gzn-5Qq93ty_bB7J7un_cbnakFbLIpDRF2SvZttQoIZUEWVLQvFKsoryUshUayq5pKm1EpXrdAZd9pVmvacOqRvAVuvzZ3cfwMZqU68Gm1jgH3oQx1YpRqTjjk3jxK47NYLp6H-0A8Vj_PYZ_AXzmaKA |
| CitedBy_id | crossref_primary_10_1016_j_heliyon_2023_e23946 crossref_primary_10_1016_j_rigapp_2005_12_004 crossref_primary_10_1159_000446043 crossref_primary_10_7759_cureus_14619 crossref_primary_10_1016_j_cveq_2007_04_001 crossref_primary_10_1016_S1726_4901_09_70064_4 crossref_primary_10_1177_175114370400500325 crossref_primary_10_1124_dmd_109_031989 crossref_primary_10_1371_journal_pone_0199153 crossref_primary_10_1016_j_beha_2005_01_004 crossref_primary_10_1097_CCM_0000000000001825 crossref_primary_10_1007_s11908_004_0033_2 crossref_primary_10_1002_bio_4421 crossref_primary_10_1007_s00390_010_0166_5 crossref_primary_10_1016_j_biologicals_2015_07_003 crossref_primary_10_1007_s40140_014_0067_4 crossref_primary_10_1017_S1481803500012033 crossref_primary_10_5694_j_1326_5377_2004_tb06258_x crossref_primary_10_1007_BF03021706 crossref_primary_10_1007_s00134_004_2385_3 crossref_primary_10_1097_01_CCM_0000239422_59433_20 crossref_primary_10_1007_s12185_020_03011_8 crossref_primary_10_1007_s00390_005_0578_9 crossref_primary_10_1111_j_1778_428X_2001_tb00038_x crossref_primary_10_1097_01_CCM_0000159853_63127_0D crossref_primary_10_1097_00029330_200811020_00028 crossref_primary_10_1111_j_1778_428X_2003_tb00283_x crossref_primary_10_1093_intqhc_mzv005 crossref_primary_10_4103_ija_IJA_398_19 crossref_primary_10_1371_journal_pone_0180750 crossref_primary_10_1016_j_amjsurg_2013_08_055 crossref_primary_10_1097_01_CCM_0000217923_53680_4C crossref_primary_10_1159_000446265 crossref_primary_10_1093_ajhp_62_6_637 crossref_primary_10_1016_j_jcrc_2011_12_003 crossref_primary_10_1177_0091270010372107 crossref_primary_10_1056_NEJMoa040232 crossref_primary_10_1034_j_1399_6576_2003_00129_x crossref_primary_10_1016_j_medine_2013_08_003 crossref_primary_10_25259_JNRP_372_2023 crossref_primary_10_1016_j_annfar_2010_05_035 crossref_primary_10_3390_ijms24032333 crossref_primary_10_1016_j_pan_2025_08_012 crossref_primary_10_1592_phco_23_1_88_31914 crossref_primary_10_1016_S0750_7658_02_00851_1 crossref_primary_10_1016_j_bas_2025_104223 crossref_primary_10_1053_j_jvca_2008_02_017 crossref_primary_10_1111_anae_14252 crossref_primary_10_1097_BCR_0000000000000201 crossref_primary_10_1038_ncpgasthep0680 crossref_primary_10_1097_TA_0b013e318176cc66 crossref_primary_10_1164_rccm_200208_909ST crossref_primary_10_1186_s13054_014_0602_1 crossref_primary_10_3390_ijms241612551 crossref_primary_10_1097_CCM_0000000000002010 crossref_primary_10_5812_aapm_30326 crossref_primary_10_1213_01_ANE_0000061582_09963_FD crossref_primary_10_1586_14787210_4_3_395 crossref_primary_10_1111_j_1778_428X_2003_tb00179_x crossref_primary_10_2165_00003088_200544100_00002 crossref_primary_10_1046_j_1435_6935_2002_00025_x crossref_primary_10_1097_01_TA_0000064525_03761_0C crossref_primary_10_1080_07853890_2019_1693056 crossref_primary_10_1016_j_tmrv_2009_09_005 crossref_primary_10_1097_00003643_200210000_00001 crossref_primary_10_1002_jssc_201100269 crossref_primary_10_1186_cc6812 crossref_primary_10_1007_s00108_006_1587_x crossref_primary_10_1097_BCR_0000000000000421 crossref_primary_10_1046_j_1399_6576_2003_00239_x crossref_primary_10_1080_078538902321117832 crossref_primary_10_2165_00003495_200464080_00004 crossref_primary_10_1097_00003643_200306000_00002 crossref_primary_10_1007_s00134_004_2511_2 crossref_primary_10_1016_S0733_8627_02_00038_X crossref_primary_10_7182_prtr_16_3_u7r829476x3p6883 crossref_primary_10_1177_0148607106030005380 crossref_primary_10_1111_j_1399_6576_2005_00711_x crossref_primary_10_1111_j_1537_2995_2005_00667_x crossref_primary_10_1186_s13063_015_0866_z crossref_primary_10_1186_cc3895 crossref_primary_10_1186_s13054_014_0702_y crossref_primary_10_1016_j_rmed_2003_07_009 crossref_primary_10_1111_j_1476_4431_2012_00728_x crossref_primary_10_1525_can_2006_21_4_535 crossref_primary_10_1097_00003246_200301000_00061 crossref_primary_10_1111_j_1399_6576_2008_01798_x crossref_primary_10_1002_app_26187 crossref_primary_10_1177_0885066605279955 crossref_primary_10_1007_s12028_016_0259_5 crossref_primary_10_1177_0115426505020003314 crossref_primary_10_1007_s00701_024_06289_3 crossref_primary_10_1177_1049909113501851 crossref_primary_10_1097_01_NAN_0000313657_50163_b2 crossref_primary_10_1378_chest_126_1_311 crossref_primary_10_1213_00000539_200302000_00001 crossref_primary_10_1097_01_CCM_0000115259_05303_91 crossref_primary_10_1007_s00228_024_03664_y crossref_primary_10_1016_S1441_2772_23_02039_2 crossref_primary_10_1136_ebn_8_2_36 crossref_primary_10_1016_j_amjsurg_2016_11_023 crossref_primary_10_1016_S1726_4901_09_70061_9 crossref_primary_10_1007_s00134_012_2472_9 crossref_primary_10_1517_14740338_6_4_407 crossref_primary_10_1097_01_CCM_0000114574_18641_5D crossref_primary_10_1097_01_shk_0000157302_69125_f8 crossref_primary_10_1097_ALN_0000000000001051 crossref_primary_10_1016_j_ccell_2003_09_007 crossref_primary_10_1002_jpen_1451 crossref_primary_10_1097_00075198_200208000_00005 crossref_primary_10_1111_j_1741_6892_2004_00468_x crossref_primary_10_1016_j_bpa_2008_11_004 crossref_primary_10_1016_j_jcrc_2017_06_002 crossref_primary_10_1097_01_CCN_0000313327_58868_c1 crossref_primary_10_1128_IAI_00116_17 crossref_primary_10_1016_j_burns_2007_09_005 crossref_primary_10_1016_j_critrevonc_2017_11_008 crossref_primary_10_1186_cc13151 crossref_primary_10_1016_j_suc_2006_09_005 crossref_primary_10_1097_01_CCM_0000239119_57544_0C crossref_primary_10_1097_00000539_200302000_00001 crossref_primary_10_1016_j_ejim_2013_05_015 crossref_primary_10_1097_01_CCM_0000065271_23556_FF crossref_primary_10_1097_01_CCM_0000142574_00425_E9 crossref_primary_10_1111_trf_12998 crossref_primary_10_1007_s11248_008_9229_9 crossref_primary_10_1016_j_suc_2012_08_014 crossref_primary_10_1097_01_mat_0000183474_01675_3a crossref_primary_10_1007_s00134_004_2415_1 crossref_primary_10_1097_01_CCM_0000156231_17436_0F crossref_primary_10_1097_ACO_0b013e328339384e crossref_primary_10_1016_j_ccc_2006_03_009 crossref_primary_10_1007_s40138_023_00268_1 crossref_primary_10_3389_fnut_2021_728353 crossref_primary_10_1016_j_jcrc_2006_11_005 crossref_primary_10_1016_S1130_6343_11_70006_X crossref_primary_10_1016_j_clp_2005_12_002 crossref_primary_10_1097_CNQ_0000000000000170 crossref_primary_10_1111_j_1778_428X_2003_tb00180_x crossref_primary_10_1002_pds_1328 crossref_primary_10_1093_bja_aep194 crossref_primary_10_1016_S1279_7960_05_83741_6 crossref_primary_10_1016_S0002_9610_02_01118_2 crossref_primary_10_1089_neu_2018_5778 crossref_primary_10_1164_rccm_200406_763OC crossref_primary_10_1097_01_CCM_0000163229_25456_DF crossref_primary_10_1016_j_ijbiomac_2009_04_023 crossref_primary_10_1097_01_ccx_0000166399_88635_a5 crossref_primary_10_1007_s00101_010_1734_6 crossref_primary_10_1097_PCC_0000000000000435 crossref_primary_10_1007_s12098_011_0366_4 crossref_primary_10_1213_01_ANE_0000089961_15975_78 crossref_primary_10_3389_fonc_2024_1323192 crossref_primary_10_1017_S0265021503001273 crossref_primary_10_1016_j_clp_2004_03_018 crossref_primary_10_5812_ircmj_41729 crossref_primary_10_1007_BF03040896 crossref_primary_10_3390_ijms232214175 crossref_primary_10_1093_bja_aeg233 crossref_primary_10_1053_j_jvca_2005_07_023 crossref_primary_10_1586_ers_09_49 crossref_primary_10_1111_j_1476_4431_2012_00819_x crossref_primary_10_1542_peds_2010_2972A crossref_primary_10_1097_01_CCM_0000139761_05492_D6 crossref_primary_10_1007_s10354_009_0651_2 crossref_primary_10_1097_CCM_0b013e3181ffe217 crossref_primary_10_1016_j_jclinepi_2016_01_020 crossref_primary_10_3390_diseases11020068 crossref_primary_10_1046_j_1365_2036_16_s5_3_x crossref_primary_10_1097_ACO_0b013e32834e8150 crossref_primary_10_1007_s00277_006_0096_2 crossref_primary_10_1097_01_CCM_0000142901_20873_4F crossref_primary_10_1016_S1279_7960_05_83743_X crossref_primary_10_1111_j_1537_2995_2012_03623_x crossref_primary_10_1097_00075197_200209000_00003 crossref_primary_10_1097_01_MIN_0000302481_94139_e7 crossref_primary_10_1136_ebn_5_1_13 crossref_primary_10_1016_j_annfar_2005_03_001 crossref_primary_10_1378_chest_130_3_869 crossref_primary_10_1016_S1590_8658_03_00383_9 crossref_primary_10_1002_hep_20720 crossref_primary_10_1378_chest_06_1743 crossref_primary_10_1097_01_SLA_0000055547_93484_87 crossref_primary_10_1186_cc13991 crossref_primary_10_1177_1178632917691270 crossref_primary_10_1111_j_1744_1633_2005_00270_x crossref_primary_10_1016_j_resuscitation_2010_08_028 crossref_primary_10_1007_s12028_013_9942_y crossref_primary_10_4037_ccn2005_25_2_14 crossref_primary_10_1097_01_ta_0000245973_71929_db crossref_primary_10_1079_PNS2005433 crossref_primary_10_1007_s40472_017_0142_0 crossref_primary_10_1177_1060028020963645 crossref_primary_10_1016_j_krcp_2012_04_317 crossref_primary_10_1177_152692480601600303 crossref_primary_10_1089_neu_2015_4233 crossref_primary_10_1097_ACO_0b013e32833724da crossref_primary_10_1590_S1516_31802010000500009 crossref_primary_10_1007_s12028_010_9392_8 crossref_primary_10_1016_j_jgyn_2014_09_027 crossref_primary_10_1371_journal_pone_0191741 crossref_primary_10_1186_s13063_020_04921_y crossref_primary_10_1097_01_CCM_0000142984_44321_A4 crossref_primary_10_1097_MCC_0000000000000028 crossref_primary_10_1097_MCO_0b013e32832a3e1a crossref_primary_10_3904_kjim_2012_27_1_13 crossref_primary_10_1136_jramc_151_02_01 crossref_primary_10_1016_j_suc_2008_09_001 crossref_primary_10_1111_j_1778_428X_2007_00075_x crossref_primary_10_1016_j_mam_2011_12_002 crossref_primary_10_5005_ijccm_8_1_14 crossref_primary_10_3171_jns_2004_100_4_0585 crossref_primary_10_1097_01_aco_0000084478_59960_76 crossref_primary_10_1053_j_nainr_2004_09_002 crossref_primary_10_1093_bja_aep393 crossref_primary_10_1097_CPM_0b013e3181856410 crossref_primary_10_3171_jns_2004_100_4_0581 crossref_primary_10_1007_s00134_006_0188_4 crossref_primary_10_1007_s11095_006_9933_1 crossref_primary_10_1177_0885066610394318 crossref_primary_10_1056_NEJMoa1305727 crossref_primary_10_1002_hep_20862 crossref_primary_10_1097_01_shk_0000248583_33270_12 crossref_primary_10_1097_01_CCM_0000163230_41876_4B crossref_primary_10_1097_ALN_0b013e31829ff30f crossref_primary_10_1016_j_jclinane_2010_06_007 crossref_primary_10_1016_S0140_6736_02_09277_2 crossref_primary_10_1097_TA_0b013e31816c5c6c crossref_primary_10_1016_j_chroma_2010_11_074 crossref_primary_10_1517_17425255_2011_570259 crossref_primary_10_1111_j_1778_428X_2003_tb00285_x crossref_primary_10_1111_j_1476_4431_2005_00141_x crossref_primary_10_1007_s00534_008_0006_1 crossref_primary_10_1097_01_sla_0000133359_12284_6b crossref_primary_10_1097_01_CCM_0000084846_45830_AA crossref_primary_10_1097_01_PCC_0000121304_23224_FC crossref_primary_10_1097_CCM_0b013e3181e81165 crossref_primary_10_1038_jp_2008_244 crossref_primary_10_1016_j_bpa_2012_10_005 crossref_primary_10_1016_j_ehbc_2004_09_016 crossref_primary_10_1097_00003643_200310000_00003 crossref_primary_10_1177_0115426506021005462 crossref_primary_10_2460_ajvr_68_6_657 crossref_primary_10_1177_1460408606071972 crossref_primary_10_1016_S0368_2315_04_96648_3 crossref_primary_10_1378_chest_123_6_1853 crossref_primary_10_1016_j_ccm_2006_06_003 crossref_primary_10_1053_j_jvca_2007_02_017 crossref_primary_10_1016_j_medin_2013_08_005 crossref_primary_10_1007_BF03018316 crossref_primary_10_1016_j_burns_2016_08_001 crossref_primary_10_1016_j_ccm_2008_11_001 crossref_primary_10_1002_jps_23181 crossref_primary_10_2746_0425164054529481 crossref_primary_10_1097_01_CCM_0000169876_14858_91 crossref_primary_10_1161_CIRCULATIONAHA_110_971093 crossref_primary_10_1155_2011_691928 crossref_primary_10_1097_01_CCM_0000170175_18540_CD crossref_primary_10_1016_j_ygyno_2017_05_010 crossref_primary_10_1111_j_1478_5153_2007_00221_x crossref_primary_10_1111_j_1778_428X_2002_tb00066_x crossref_primary_10_1053_j_jvca_2008_03_002 crossref_primary_10_1017_S0265021503000681 crossref_primary_10_1007_s00540_010_1034_y crossref_primary_10_1186_1472_6904_4_4 crossref_primary_10_1007_s10742_006_6829_9 crossref_primary_10_1016_j_ccc_2007_07_001 crossref_primary_10_1007_s00418_010_0676_z crossref_primary_10_1111_ans_13066 crossref_primary_10_1111_j_1537_2995_2005_00566_x |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.7326/0003-4819-135-3-200108070-00007 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 11487482 |
| Genre | Research Support, Non-U.S. Gov't Meta-Analysis Journal Article |
| GroupedDBID | --- ..I .55 .GJ .XZ 23M 2WC 354 36B 39C 3O- 4.4 53G 5GY 5RE 5RS 6J9 8F7 AAKAS AAQQT AARDX AAWTL AAYOK ABBLC ABCQX ABDPE ABJNI ABOCM ABPMR ACBNA ACGFO ACGFS ADZCM AEGXH AENEX AFCHL AFFNX AHJKT AHMBA AI. AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN BZLQD C1A C45 CGR CUY CVF E3Z EBS ECM EIF EJD EMB EMOBN EX3 F5P H13 H~9 IH2 J5H K-O L7B M5~ MV1 MVM N4W NPM OBH OCB OFXIZ OGEVE OHH OVD OVIDX P2P RXW SJN SV3 TEORI TPH TR2 TWZ UKR VH1 VVN VXZ WH7 WOQ WOW X6Y X7M YFH YOC ZGI ZXP ZY1 ~H1 7X8 |
| ID | FETCH-LOGICAL-c354t-6e46f75cc0e73575a560a82971902655c38a6dbb98e397f8da25f981f80b19b32 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 305 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000170298500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0003-4819 |
| IngestDate | Thu Sep 04 20:28:27 EDT 2025 Wed Feb 19 02:36:10 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c354t-6e46f75cc0e73575a560a82971902655c38a6dbb98e397f8da25f981f80b19b32 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 11487482 |
| PQID | 71057212 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_71057212 pubmed_primary_11487482 |
| PublicationCentury | 2000 |
| PublicationDate | 2001-08-07 |
| PublicationDateYYYYMMDD | 2001-08-07 |
| PublicationDate_xml | – month: 08 year: 2001 text: 2001-08-07 day: 07 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Annals of internal medicine |
| PublicationTitleAlternate | Ann Intern Med |
| PublicationYear | 2001 |
| References | 12204032 - Ann Intern Med. 2002 Sep 3;137(5 Part 1):370-1; author reply 370-1 11730412 - Ann Intern Med. 2001 Dec 4;135(11):1008-9 11829543 - ACP J Club. 2002 Jan-Feb;136(1):2 11487488 - Ann Intern Med. 2001 Aug 7;135(3):205-8 11915791 - Evid Based Nurs. 2002 Jan;5(1):13 |
| References_xml | – reference: 11829543 - ACP J Club. 2002 Jan-Feb;136(1):2 – reference: 11487488 - Ann Intern Med. 2001 Aug 7;135(3):205-8 – reference: 12204032 - Ann Intern Med. 2002 Sep 3;137(5 Part 1):370-1; author reply 370-1 – reference: 11915791 - Evid Based Nurs. 2002 Jan;5(1):13 – reference: 11730412 - Ann Intern Med. 2001 Dec 4;135(11):1008-9 |
| SSID | ssj0003828 |
| Score | 2.252441 |
| SecondaryResourceType | review_article |
| Snippet | To test the hypothesis that albumin administration is not associated with excess mortality.
Computer searches of the MEDLINE and EMBASE databases, the Cochrane... To test the hypothesis that albumin administration is not associated with excess mortality.PURPOSETo test the hypothesis that albumin administration is not... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 149 |
| SubjectTerms | Albumins - administration & dosage Albumins - therapeutic use Bias Colloids - therapeutic use Critical Care - methods Critical Illness - mortality Critical Illness - therapy Fluid Therapy - methods Randomized Controlled Trials as Topic Rehydration Solutions - therapeutic use Research Design Risk Factors Survival Analysis |
| Title | Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/11487482 https://www.proquest.com/docview/71057212 |
| Volume | 135 |
| WOSCitedRecordID | wos000170298500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB7WB-LF9_uVg-DFuN2mSaYgyCKKB132oLC3JW1SWNCtuqsHf72TtFU8iAcvLRQKbfIx87Uz830Ax-gVT4RUPM2U5Im0KUeHOSeqIGIbGaOSMCh8q3s9HAzSfgvOm1kY31bZxMQQqG2Z-3_kbe0NaSnOXjy_cO8Z5WurtYHGDMwJIjIe03rwrRUuMMbGLy-hxLcAJxQiNPGV9tc13hGSCw8V32unw5B1pH9nmyHrXC__73lXYKlmm6xbwWMVWm68Bgt3dT19HVy_klVlkzcKGQQ6FjzDWXDuY6F1eUTnHwK7Z6zLntzUcFPrmbCyYJTxbPk0-nD2lNXd74_OsuAJMtmAh-ur-8sbXhsv8FzIZMqVS1ShZZ5HTgvic4ZokfEzuMQeYiVlLtAom2UpOqIzBVoTyyLFToFR1kkzEW_C7Lgcu21gCRaRS5XVmSLyaHJiyR2iBOhS9F9yuANHzfINCdi-WmHGrnybDJsF3IGtageGz5X-hh-kRp1gvPvnvXuwWPWMIY_0PswV9M7uAObz9-lo8noY8ELHXv_uEwqHxug |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Patient+survival+after+human+albumin+administration.+A+meta-analysis+of+randomized%2C+controlled+trials&rft.jtitle=Annals+of+internal+medicine&rft.au=Wilkes%2C+M+M&rft.au=Navickis%2C+R+J&rft.date=2001-08-07&rft.issn=0003-4819&rft.volume=135&rft.issue=3&rft.spage=149&rft_id=info:doi/10.7326%2F0003-4819-135-3-200108070-00007&rft_id=info%3Apmid%2F11487482&rft_id=info%3Apmid%2F11487482&rft.externalDocID=11487482 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4819&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4819&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4819&client=summon |